GNCA (Genocea Biosciences) NASDAQ down 97.44% to $0.0001 pre-market 13 Jan 2026: See liquidity
GNCA stock opened the pre-market session on 13 Jan 2026 at $0.0001, down 97.44% from the previous close. This dramatic move places Genocea Biosciences, Inc. (GNCA) among the top pre-market losers on NASDAQ in the United States. Volume was modest at 30,268.00 shares versus a 50‑day average near 80,568.00. The immediate drivers include long-running Chapter 11 restructuring, scarce liquidity, and weak trading interest. We examine valuation, cash metrics, the Meyka AI grade, and a short-form forecast for GNCA stock to help traders prioritize next steps.
Pre-market moves for GNCA stock
GNCA stock traded at $0.0001 in pre-market on 13 Jan 2026 after an open at $0.0007. The one‑day decline reads -97.44%, with intraday range fixed at $0.0001. Volume of 30,268.00 shares is below the 50‑day average of 80,568.00, showing limited liquidity. This low liquidity amplifies price swings and raises execution risk for larger orders.
Key drivers behind the GNCA stock drop
Genocea filed Chapter 11 on 5 July 2022, which remains a central factor in market sentiment. Ongoing restructuring reduces investor confidence and limits traditional equity value recovery. Clinical programs such as GEN-011 and GEN-009 were in early trials, but pipeline updates have been sparse since the restructuring. The lack of fresh positive clinical or commercial news has left GNCA stock exposed to steep downside moves.
Financial snapshot and valuation metrics for GNCA stock
The company shows cash per share $0.54 and book value per share $0.39 on trailing data. Enterprise value reads negative due to reported liabilities and negligible market cap, listed as $0.00. Price vs. history shows a 50‑day average near $0.00 and a 200‑day average near $0.11. Current ratio is 2.24, and research and development to revenue is 23.78%, signaling a small balance sheet with ongoing R&D spend. These metrics point to asset value but limited operational scale for recovery.
Meyka AI rates GNCA with a score out of 100 and technical view
Meyka AI rates GNCA with a score out of 100 as 58.75 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. The grade reflects moderate asset value but high event and liquidity risk. From a technical standpoint, GNCA stock is effectively at a micro‑penny trading level. Price averages collapse and relative volume is low. Traders should expect high volatility and wide spreads.
Risks and potential catalysts for GNCA stock
Primary risks include continued restructuring outcomes, potential delisting risk, and lack of operating revenue. Low liquidity increases execution and slippage risk during price moves. Catalysts that could change the view include a restructuring resolution that returns value to shareholders, new financing, a takeover bid, or credible clinical or IP monetization news. Until then, GNCA stock remains speculative.
Analyst outlook and GNCA stock forecast
There is no consensus price target or active analyst coverage in the dataset. Meyka AI’s forecast model projects $0.0001 for GNCA stock over the near term, compared with the current price of $0.0001. That implies an expected change of 0.00% versus current levels. Forecasts are model‑based projections and not guarantees. Given the balance sheet and restructuring status, upside requires positive restructuring outcomes or corporate action.
Final Thoughts
Key takeaways for GNCA stock: the pre-market price at $0.0001 on 13 Jan 2026 makes GNCA a top pre-market loser on NASDAQ in the United States. Balance sheet figures such as cash per share $0.54 and current ratio 2.24 show some asset backing, but enterprise value and market cap metrics are effectively zero. Meyka AI rates GNCA at 58.75 (Grade C+, Suggestion: HOLD), reflecting modest asset value against high restructuring and liquidity risk. Meyka AI’s forecast model projects $0.0001 for GNCA stock, implying 0.00% near‑term change from current pricing. Forecasts are model-based projections and not guarantees. Traders and investors should treat GNCA stock as highly speculative, monitor Chapter 11 developments and any restructuring announcements, and prioritise liquidity management before entering positions. For company details see the Genocea website and recent market summaries source and contextual market reporting source. Meyka AI is an AI-powered market analysis platform and provides the grade and forecast cited above.
FAQs
Why did GNCA stock drop so sharply pre-market?
GNCA stock fell on thin liquidity and lingering Chapter 11 restructuring concerns. Sparse corporate updates and low trading interest amplified the drop to $0.0001.
What is the Meyka AI grade and recommendation for GNCA stock?
Meyka AI rates GNCA 58.75 / 100, Grade C+, Suggestion HOLD. The grade balances modest assets against high restructuring and liquidity risk.
What is the near-term forecast for GNCA stock?
Meyka AI’s forecast model projects $0.0001 for GNCA stock, implying 0.00% near-term change. Forecasts are projections and not guarantees. Monitor restructuring updates.
Does Genocea have meaningful cash or assets per share?
Trailing metrics show cash per share $0.54 and book value per share $0.39. These figures suggest some asset backing but do not ensure equity recovery.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
